Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Prempro DTC Campaign Touts Lowest Approved Dose Of Hormone Therapy

Executive Summary

Wyeth's direct-to-consumer advertising campaign for Prempro highlights the hormone replacement therapy's lowest dose approved by FDA
Advertisement

Related Content

Beyond Hormone Therapy: Signs Of Life In Pipeline For Menopausal Women
Wyeth Using Unbranded Ads To Stimulate Premarin, Prempro Growth
Wyeth Using Unbranded Ads To Stimulate Premarin, Prempro Growth
FDA Takes Relaxed Stance On DTC Ads For Products With “Black Box”
Warner Chilcott Femtrace Launch Expected In First Quarter 2005
Hormone Therapy Dementia “Black Box” Warning Sought By FDA
Wyeth Tests The Waters: Prempro “Pilot” DTC Ad Planned For Fall
Wyeth Tests The Waters: Prempro “Pilot” DTC Ad Planned For Fall
Wyeth Prempro Gets Dementia Warning; FDA Considering HRT Class Labeling
Prempro Cancer Risk Addressed In 550,000 Physician Letters, Label Review

Topics

Advertisement
UsernamePublicRestriction

Register

PS044554

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel